A new American Cancer Society report reveals deep cancer mortality disparities across the U.S., with rural communities, lower ...

Deaths from cancer have declined by 33% since 1991, averting 4.1 million deaths. However, more people are being diagnosed with cancer than ever before, and at an earlier age, according to a major new ...

A recent analysis showed the rate of uninsured children in the U.S. grew from 2022 to 2024. Experts say this could lead to ...

Heart disease and cancer were again the leading causes of death in the U.S. in 2024, according to a CDC report published Sept. 10, which analyzed 99.9% of 2024 death records as of June 1, 2025. At the ...

Overall cancer deaths in the United States continue to decline, but trends are mixed when it comes to deaths associated with specific cancer types and overall cancer incidence, according to the 2025 ...

There will be an expected 18.6 million deaths from cancer globally in 2050, up from 10.4 million cancer deaths in 2023, according to a study published Sept. 24 in The Lancet. For their analysis, ...

In new research on the status of cancer disparities in the United States, American Cancer Society (ACS) scientists report higher cancer mortality rates among adults living in rural areas, certain ...

THROWN AWAY. NEW ON SEVEN CANCER DEATH RATES ARE ON THE DECLINE. A NEW REPORT SHOWS THAT DEATHS BY CANCER DROPPED 1.5% PER YEAR FROM 2018 TO 2022. THE REPORT SUGGESTS THE DECLINE IS DUE TO BETTER ...

Higher Life’s Simple 7 cardiovascular health scores were associated with lower long-term all-cause and cancer mortality in ...

While rich countries manage to reduce deaths thanks to prevention and better treatments, low- and middle-income countries see diagnoses and deaths continue to rise worryingly, according to a study by ...

Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.